Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses.

Rondon-Berrios H, Berl T.

Front Med (Lausanne). 2017 Aug 21;4:141. doi: 10.3389/fmed.2017.00141. eCollection 2017. Review.

2.

Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.

Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Kikuchi M, Shobu Y.

Clin Exp Nephrol. 2018 Apr;22(2):299-308. doi: 10.1007/s10157-017-1447-0. Epub 2017 Jul 24.

3.

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.

Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Shobu Y, Kikuchi M.

BMC Nephrol. 2016 Sep 30;17(1):141.

4.

Vasopressin receptor antagonists: Characteristics and clinical role.

Rondon-Berrios H, Berl T.

Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):289-303. doi: 10.1016/j.beem.2016.02.004. Epub 2016 Feb 16. Review.

PMID:
27156765
5.

Vasopressin Antagonists.

Berl T.

N Engl J Med. 2015 Sep 3;373(10):981. doi: 10.1056/NEJMc1508385. No abstract available.

PMID:
26332561
6.

Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management.

Rondon-Berrios H, Berl T.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2268-78. doi: 10.2215/CJN.00170115. Epub 2015 Jun 24. Review.

7.

Vasopressin antagonists.

Berl T.

N Engl J Med. 2015 Jun 4;372(23):2207-16. doi: 10.1056/NEJMra1403672. Review. No abstract available.

PMID:
26039601
8.

Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.

Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M.

J Am Soc Nephrol. 2015 Jul;26(7):1732-46. doi: 10.1681/ASN.2014010042. Epub 2014 Oct 27.

9.

Dysnatremias in patients with kidney disease.

Combs S, Berl T.

Am J Kidney Dis. 2014 Feb;63(2):294-303. doi: 10.1053/j.ajkd.2013.09.017. Epub 2013 Nov 14. Review.

10.

Where vaptans do and do not fit in the treatment of hyponatremia.

Jovanovich AJ, Berl T.

Kidney Int. 2013 Apr;83(4):563-7. doi: 10.1038/ki.2012.402. Epub 2012 Dec 19. Review.

11.

An elderly patient with chronic hyponatremia.

Berl T.

Clin J Am Soc Nephrol. 2013 Mar;8(3):469-75. doi: 10.2215/CJN.03100312. Epub 2012 Oct 4. Review.

12.

Differential diagnosis of hyponatraemia.

Thompson C, Berl T, Tejedor A, Johannsson G.

Best Pract Res Clin Endocrinol Metab. 2012 Mar;26 Suppl 1:S7-15. doi: 10.1016/S1521-690X(12)70003-9.

PMID:
22469249
13.

Mortality and serum sodium in CKD--yet another U‑shaped curve.

Jovanovich A, Berl T.

Nat Rev Nephrol. 2012 May;8(5):261-3. doi: 10.1038/nrneph.2012.65.

PMID:
22473511
14.

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.

Smink PA, Bakker SJ, Laverman GD, Berl T, Cooper ME, de Zeeuw D, Lambers Heerspink HJ.

J Hypertens. 2012 May;30(5):1022-8. doi: 10.1097/HJH.0b013e32835200f9.

PMID:
22388234
15.

Pyridorin in type 2 diabetic nephropathy.

Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group.

J Am Soc Nephrol. 2012 Jan;23(1):131-6. doi: 10.1681/ASN.2011030272. Epub 2011 Oct 27.

16.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; Collaborative Study Group.

J Am Soc Nephrol. 2012 Jan;23(1):123-30. doi: 10.1681/ASN.2011040378. Epub 2011 Oct 27.

17.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group.

Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Erratum in: Am J Kidney Dis. 2012 Feb;59(2):318.

PMID:
21872376
18.

Is osmotic demyelination a concern dialyzing hyponatremic patients?

Sirota JC, Berl T.

Semin Dial. 2011 Jul-Aug;24(4):407-9. doi: 10.1111/j.1525-139X.2011.00899.x. Epub 2011 Jul 29. No abstract available.

PMID:
21801217
19.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ.

Eur Heart J. 2011 Jun;32(12):1493-9. doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.

PMID:
21421598
20.

Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.

Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators.

Eur J Endocrinol. 2011 May;164(5):725-32. doi: 10.1530/EJE-10-1078. Epub 2011 Feb 11.

21.

Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.

Circ Heart Fail. 2011 Jan;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558. Epub 2010 Oct 29.

PMID:
21036889
22.

Biomarkers in kidney and heart disease.

Maisel AS, Katz N, Hillege HL, Shaw A, Zanco P, Bellomo R, Anand I, Anker SD, Aspromonte N, Bagshaw SM, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, House AA, Mankad S, McCullough P, Mebazaa A, Palazzuoli A, Ponikowski P, Ronco F, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ronco C; Acute Dialysis Quality Initiative consensus group.

Nephrol Dial Transplant. 2011 Jan;26(1):62-74. doi: 10.1093/ndt/gfq647. Epub 2010 Oct 26.

PMID:
20978142
23.

Effects of 2-bromoethanamine on TonEBP expression and its possible role in induction of renal papillary necrosis in mice.

Andres-Hernando A, Lanaspa MA, Li N, Cicerchi C, Roncal-Jimenez C, Cantor GH, Sorribas V, Rivard CJ, Berl T.

Toxicol Sci. 2010 Dec;118(2):510-20. doi: 10.1093/toxsci/kfq261. Epub 2010 Sep 7.

24.

The expression of aquaporin-1 in the medulla of the kidney is dependent on the transcription factor associated with hypertonicity, TonEBP.

Lanaspa MA, Andres-Hernando A, Li N, Rivard CJ, Cicerchi C, Roncal-Jimenez C, Schrier RW, Berl T.

J Biol Chem. 2010 Oct 8;285(41):31694-703. doi: 10.1074/jbc.M109.093690. Epub 2010 Jul 16.

25.

ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.

Davenport A, Anker SD, Mebazaa A, Palazzuoli A, Vescovo G, Bellomo R, Ponikowski P, Anand I, Aspromonte N, Bagshaw S, Berl T, Bobek I, Cruz DN, Daliento L, Haapio M, Hillege H, House A, Katz N, Maisel A, Mankad S, McCullough P, Ronco F, Shaw A, Sheinfeld G, Soni S, Zamperetti N, Zanco P, Ronco C; Acute Dialysis Quality Initiative (ADQI) consensus group.

Nephrol Dial Transplant. 2010 Jul;25(7):2077-89. doi: 10.1093/ndt/gfq252. Epub 2010 May 20.

PMID:
20494894
26.

Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI).

Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P; Acute Dialysis Quality Initiative (ADQI) consensus group.

Contrib Nephrol. 2010;165:54-67. doi: 10.1159/000313745. Epub 2010 Apr 20.

PMID:
20427956
27.

Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.

McCullough PA, Haapio M, Mankad S, Zamperetti N, Massie B, Bellomo R, Berl T, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bobek I, Cruz DN, Daliento L, Davenport A, Hillege H, House AA, Katz N, Maisel A, Mebazaa A, Palazzuoli A, Ponikowski P, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zanco P, Ronco C, Berl T; Acute Dialysis Quality Initiative (ADQI) Consensus Group.

Nephrol Dial Transplant. 2010 Jun;25(6):1777-84. doi: 10.1093/ndt/gfq180. Epub 2010 Apr 6. No abstract available.

PMID:
20375030
28.

A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion.

Berl T, Rastegar A.

Am J Kidney Dis. 2010 Apr;55(4):742-8. doi: 10.1053/j.ajkd.2009.12.024. No abstract available.

PMID:
20338465
29.

Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference.

House AA, Anand I, Bellomo R, Cruz D, Bobek I, Anker SD, Aspromonte N, Bagshaw S, Berl T, Daliento L, Davenport A, Haapio M, Hillege H, McCullough P, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Ronco C; Acute Dialysis Quality Initiative Consensus Group.

Nephrol Dial Transplant. 2010 May;25(5):1416-20. doi: 10.1093/ndt/gfq136. Epub 2010 Mar 12. No abstract available.

PMID:
20228069
30.

Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.

Bagshaw SM, Cruz DN, Aspromonte N, Daliento L, Ronco F, Sheinfeld G, Anker SD, Anand I, Bellomo R, Berl T, Bobek I, Davenport A, Haapio M, Hillege H, House A, Katz N, Maisel A, Mankad S, McCullough P, Mebazaa A, Palazzuoli A, Ponikowski P, Shaw A, Soni S, Vescovo G, Zamperetti N, Zanco P, Ronco C; Acute Dialysis Quality Initiative Consensus Group.

Nephrol Dial Transplant. 2010 May;25(5):1406-16. doi: 10.1093/ndt/gfq066. Epub 2010 Feb 25. Review. No abstract available.

PMID:
20185818
31.

Oral tolvaptan is safe and effective in chronic hyponatremia.

Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators.

J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.

32.

Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes.

Maahs DM, Snell-Bergeon JK, Hokanson JE, Kinney GL, Berl T, Rewers M, Ogden LG.

Diabetes Technol Ther. 2010 Jan;12(1):25-33. doi: 10.1089/dia.2009.0086.

33.

Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative.

Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P; Acute Dialysis Quality Initiative (ADQI) consensus group.

Eur Heart J. 2010 Mar;31(6):703-11. doi: 10.1093/eurheartj/ehp507. Epub 2009 Dec 25.

34.

How do kidney cells adapt to survive in hypertonic inner medulla?

Berl T.

Trans Am Clin Climatol Assoc. 2009;120:389-401. Review.

35.

ZAC1 is up-regulated by hypertonicity and decreases sorbitol dehydrogenase expression, allowing accumulation of sorbitol in kidney cells.

Lanaspa MA, Andres-Hernando A, Rivard CJ, Dai Y, Li N, Berl T.

J Biol Chem. 2009 Jul 24;284(30):19974-81. doi: 10.1074/jbc.M109.001792. Epub 2009 May 7.

36.

Care of undocumented individuals with ESRD: a national survey of US nephrologists.

Hurley L, Kempe A, Crane LA, Davidson A, Pratte K, Linas S, Dickinson LM, Berl T.

Am J Kidney Dis. 2009 Jun;53(6):940-9. doi: 10.1053/j.ajkd.2008.12.029. Epub 2009 Mar 26.

PMID:
19327878
37.

Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.

Berl T.

J Renin Angiotensin Aldosterone Syst. 2009 Mar;10(1):1-8. doi: 10.1177/1470320309102747. Review.

PMID:
19286752
38.

Different ways to die: cell death modes of the unicellular chlorophyte Dunaliella viridis exposed to various environmental stresses are mediated by the caspase-like activity DEVDase.

Jiménez C, Capasso JM, Edelstein CL, Rivard CJ, Lucia S, Breusegem S, Berl T, Segovia M.

J Exp Bot. 2009;60(3):815-28. doi: 10.1093/jxb/ern330. Epub 2009 Feb 27.

39.

Hypertonic stress increases claudin-4 expression and tight junction integrity in association with MUPP1 in IMCD3 cells.

Lanaspa MA, Andres-Hernando A, Rivard CJ, Dai Y, Berl T.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15797-802. doi: 10.1073/pnas.0805761105. Epub 2008 Oct 7.

40.

Nucleoporin 88 (Nup88) is regulated by hypertonic stress in kidney cells to retain the transcription factor tonicity enhancer-binding protein (TonEBP) in the nucleus.

Andres-Hernando A, Lanaspa MA, Rivard CJ, Berl T.

J Biol Chem. 2008 Sep 5;283(36):25082-90. doi: 10.1074/jbc.M802381200. Epub 2008 Jul 7.

41.

Vasopressin antagonists in the treatment of water-retaining disorders.

Kumar S, Berl T.

Semin Nephrol. 2008 May;28(3):279-88. doi: 10.1016/j.semnephrol.2008.03.008. Review.

PMID:
18519088
42.

Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.

Berl T.

Nephrol Dial Transplant. 2008 Aug;23(8):2443-7. doi: 10.1093/ndt/gfn239. Epub 2008 May 8. Review. No abstract available.

PMID:
18467376
43.

A metabonomic and proteomic analysis of changes in IMCD3 cells chronically adapted to hypertonicity.

Klawitter J, Rivard CJ, Brown LM, Capasso JM, Almeida NE, Maunsbach AB, Pihakaski-Maunsbach K, Berl T, Leibfritz D, Christians U, Chan L.

Nephron Physiol. 2008;109(1):p1-10. doi: 10.1159/000129074. Epub 2008 May 5.

PMID:
18460876
44.

Impact of solute intake on urine flow and water excretion.

Berl T.

J Am Soc Nephrol. 2008 Jun;19(6):1076-8. doi: 10.1681/ASN.2007091042. Epub 2008 Mar 12.

45.

The Adrogue-Madias formula revisited.

Berl T.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1098-9. Epub 2007 Oct 10. No abstract available.

46.

Long-term outcomes after coronary artery bypass grafting: preoperative kidney function is prognostic.

Chonchol MB, Aboyans V, Lacroix P, Smits G, Berl T, Laskar M.

J Thorac Cardiovasc Surg. 2007 Sep;134(3):683-9.

47.

Kidney-heart interactions: epidemiology, pathogenesis, and treatment.

Berl T, Henrich W.

Clin J Am Soc Nephrol. 2006 Jan;1(1):8-18. Epub 2005 Dec 22. Review. No abstract available.

48.

The tight junction protein, MUPP1, is up-regulated by hypertonicity and is important in the osmotic stress response in kidney cells.

Lanaspa MA, Almeida NE, Andres-Hernando A, Rivard CJ, Capasso JM, Berl T.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13672-7. Epub 2007 Aug 9.

49.

Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes.

Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M.

Diabetes. 2007 Nov;56(11):2774-9. Epub 2007 Jul 27.

50.

Clinical practice. The syndrome of inappropriate antidiuresis.

Ellison DH, Berl T.

N Engl J Med. 2007 May 17;356(20):2064-72. Review. No abstract available.

PMID:
17507705

Supplemental Content

Support Center